Windtree Therapeutics, a Nasdaq-listed company traditionally focused on biotech, announced a bold shift into the crypto sphere: a $60 million securities purchase agreement to acquire BNB, the native token of Binance Chain.
The deal, spearheaded by Build and Build Corp, outlines immediate BNB acquisitions and the purchase of shares in Osprey BNB Chain Trust. Moreover, the framework includes an option for up to $140 million more in follow-on subscriptions—bringing total potential funding to $200 million, pending shareholder approval and other closing conditions.
If finalized, this move positions Windtree as the first Nasdaq-listed firm to offer direct exposure to BNB via its corporate treasury—signaling a diversification strategy that goes beyond the more common Bitcoin or Ethereum holdings. CEO Jed Latkin emphasized that the capital raised will support the launch and execution of a robust BNB treasury strategy, leveraging custody solutions and yield-generation mechanisms.
BNB ranks among the world’s top 10 cryptocurrencies by market cap, with average daily trading volumes exceeding $2 billion, bolstered further by its role as the native token of Binance—the world’s largest crypto exchange. Binance founder Changpeng Zhao, known as CZ, acknowledged this trend, referring to companies like Windtree as part of a growing wave of “micro-strategies” centered on BNB.
This development comes amid a broader corporate treasury trend: firms previously shy of crypto exposure are expanding into altcoins with strategic allocations. While Bitcoin remains dominant, tokens like Ethereum, XRP, Solana—and now BNB—are becoming increasingly appealing targets.
Still, this pivot from therapeutics to BNB-heavy treasury management is steep, with success depending on shareholder consent and an evolving regulatory landscape. Yet as Windtree paves the way, its bold move may catalyze broader corporate acceptance of altcoin treasury strategies.
